MECHELEN, BELGIUM--(Marketwire - May 30, 2012) - Galapagos NV (Euronext: GLPG) and Ono
Pharmaceutical Co., Ltd. (TSE: 4528) announced today that they have signed an
additional collaboration agreement focused on discovering novel targets in the
field of allergic diseases including atopic dermatitis and bronchial asthma.
the new agreement, Galapagos' service division BioFocus will use its
SilenceSelect® platform to deliver validated targets to Ono. Ono aims to
modulators for these targets and generate novel drug candidates. Financial
details were undisclosed.
"We are delighted with the success of our relationship with Ono," said Dr
Newton, SVP Galapagos Services and Managing Director BioFocus. "The start of
new collaboration one year after the first one is testament to our target
discovery platform and the strength of our partnership."
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer
and Executive Director, Discovery and Research of Ono commented: "This new
project builds upon a novel human primary cell-based assay developed by
in the field of allergic diseases, an area with significant unmet medical
needs. We are excited to apply BioFocus' target discovery platform to
and validate novel drug targets."
Ono Pharmaceutical Co., Ltd. is an R&D-oriented pharmaceutical company
specialized in creating innovative medicines for the treatment of various
indications with unmet medical need at the frontline of healthcare. The
focuses on drug discovery leads that are high in certainty and
globally-competitive, promoting alliances with biopharmaceutical companies in
the US and
Europe as well as research collaborations with universities and other research
institutions. Ono's drug discovery efforts focus on the therapeutic
of bioactive lipids and enzyme inhibitors in the areas of inflammation,
autoimmune disease, cancer, cardiovascular diseases and CNS disorders. The
Company's strategic partnerships are not solely directed towards the discovery
of new drug candidates, but also include international in-licensing agreements
to strengthen Ono's ever-expanding development pipeline. Ono already
manufactures and markets a broad portfolio of prescription pharmaceuticals
targeting a wide range of indications such as Alzheimer's disease, type II
diabetes, osteoporosis, chemotherapy-induced nausea and bronchial asthma. Ono
is a firmly established pharmaceutical company, headquartered in Osaka, Japan
and listed on the Tokyo Stock Exchange since 1963. More information at
Galapagos (Euronext: GLPG) (PINKSHEETS: GLPYY) is a mid-size biotechnology
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing GLPG0634, as
well as one of the largest pipelines in biotech, with four programs in
development and over 50 discovery programs. The Galapagos Group has about 800
employees and operates facilities in six countries, with global headquarters
Mechelen, Belgium. More info at: www.glpg.com
BioFocus provides integrated drug discovery that delivers pre-clinical drug
candidates in all therapeutic areas with strong capability in
diseases, inflammatory diseases and with a growing track record of delivering
candidates against rare and neglected diseases. BioFocus has advanced and
comprehensive drug discovery capabilities that are applied to client projects
deliver targets, hits, leads and candidate pre-clinical drugs. The company
employs 250 exceptionally qualified and industry experienced scientists at its
three research centers in the UK, Switzerland and the Netherlands. Since its
foundation in 1997, BioFocus has striven to produce high quality data for its
clients and this quality is assured by ISO9001 qualification validated by
regular, independent inspection of all BioFocus research centers. More
information at www.biofocus.com.
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
SilenceSelect® is platform technology which utilizes human primary cell
with ribonucleic acid (RNA) interference (RNAi) through proprietary
technology to find novel targets. RNAi is a technology that controls
activity of specific genes by introducing small double-stranded RNA
into cells. Protein expression from a specific gene is suppressed by
introduction of these artificial RNAs which allows complex functional studies
the protein's role in a specific disease pathway to be performed.
employs the unique properties of adenoviruses to apply RNAi in human
BioFocus® and SilenceSelect® are trademarks of Galapagos NV
affiliates © Copyright 2012 Galapagos NV.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE